Acon Bzo One Step Benzodiazepines Test Strip and 1 more
Enzyme Immunoassay, Benzodiazepine. 510(k) K012300, from ACON Laboratories, Inc. (San Diego, CA). Product code JXM, class 2.
As of Nov 20, 2026, K012300 is an FDA 510(k) held by ACON Laboratories, Inc., substantially equivalent on Sep 17, 2001 after 59 days, with no recalls tied to it in FDA's recall database.
- Review time: 59 days
- Recalls: 0
- Cited as a predicate by: 5 devices
The ACON BZO One Step Benzodiazepines Test Strip and ACON BZO One Step Benzodiazepines Test Device are rapid chromatographic immunoassays for the qualitative detection of Benzodiazepines in human urine at a cut-off concentration of 300 ng/mL set relative to oxazepam, a major metabolite of benzodiazepines.
- Accusign Bzo, Biosign Bzo, Status BzoK991079 · Princeton BioMeditech Corp. · Apr 15, 1999
- Polymed Therapeutics Fastep Dipstick Drugs of Abuse Screen Device and Dipcard Drugs of Abuse Screen DeviceK121065 · Polymed Therapeutics, Inc. · May 24, 2013
- First Sign Drug of Abuse Urine Screening TestK052197 · W.H.P.M., Inc. · Jun 9, 2006
- Acon Tri-Fect Drug Screen Test DeviceK041743 · ACON Laboratories, Inc. · Sep 9, 2004
- Acon Multi-Clin Drug Screen Test DeviceK041685 · ACON Laboratories, Inc. · Aug 30, 2004
- Acon One Step Multi-Drug Multi-Line Screen Test Card, Acon One Step Multi-Drug Multi-Line Screen Test DeviceK023946 · ACON Laboratories, Inc. · Feb 5, 2003
- Alinity c Benzodiazepines Reagent KitK243498 · Microgenics Corporation · Dec 11, 2024
- ONLINE DAT Benzodiazepines IIK221765 · Roche Diagnostics · Dec 23, 2022
- Document
- 510(k) summary (PDF) ↗
- Type
- Traditional
- Received
- Jul 20, 2001
- Review panel
- Clinical Toxicology
- Regulation
- 21 CFR 862.3170
One page per 510(k), De Novo and original PMA. Recalls are those FDA's recall database ties to this number; recalls of related devices that cite another number are not shown. Refreshed weekly. Predicates are read by Arca from the text of FDA's 510(k) summary PDFs, most of them scans: a device number counts when the summary names it as a predicate or as the device it is substantially equivalent to. About 97% of those read were right on a sample we checked by hand; summaries from before 2000 often name predicates without a number, so older devices show fewer. Pivotal studies are read by a model from FDA's De Novo decision summaries and PMA SSEDs; a count or result is shown only when its numbers appear in FDA's text. openFDA device 510(k), PMA and recall files